Genmab initiates share buy-back program worth up to 725 million DKK

Danish biotechnology company Genmab announced the initiation of a share buy-back program worth up to 725 million Danish Krone (DKK) on June 15, 2023, aiming to enhance shareholder value and demonstrate confidence in the company's financial position and future growth prospects. The buy-back program represents a significant financial commitment from Genmab, one of Denmark's leading biotechnology firms specializing in antibody therapeutics. The company's board authorized the program, which will allow Genmab to repurchase its own shares on the open market over an unspecified period. This move follows several quarters of strong financial performance for the company, which has developed several successful antibody-based treatments for various cancers and autoimmune diseases. Share buy-back programs are common strategies used by companies with strong cash positions and limited investment opportunities. By reducing the number of outstanding shares, Genmab can potentially increase earnings per share and return capital to shareholders. The announcement was well-received by investors, with Genmab's stock showing positive movement following the news. Industry analysts view this as a positive signal of Genmab's confidence in its pipeline of therapeutic products and its ability to generate consistent cash flows in the coming years.